The Biotech Growth Trust (BIOG) Competitors

The Biotech Growth Trust logo
GBX 1,354 +16.00 (+1.20%)
As of 12:28 PM Eastern

BIOG vs. JPE, MRCH, TFIF, BBGI, and USA

Should you buy The Biotech Growth Trust stock or one of its competitors? The Biotech Growth Trust's main competitors and comparable companies include JPMorgan Elect plc ­- Managed Growth (JPE), The Merchants Trust (MRCH), TwentyFour Income (TFIF), BBGI Global Infrastructure (BBGI), and Baillie Gifford US Growth (USA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "asset management & custody banks" industry.

How does The Biotech Growth Trust compare to JPMorgan Elect plc ­- Managed Growth?

JPMorgan Elect plc ­- Managed Growth (LON:JPE) and The Biotech Growth Trust (LON:BIOG) are both small-cap finance companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

10.5% of The Biotech Growth Trust shares are owned by institutional investors. 3.1% of The Biotech Growth Trust shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, The Biotech Growth Trust had 1 more articles in the media than JPMorgan Elect plc ­- Managed Growth. MarketBeat recorded 1 mentions for The Biotech Growth Trust and 0 mentions for JPMorgan Elect plc ­- Managed Growth. The Biotech Growth Trust's average media sentiment score of 1.45 beat JPMorgan Elect plc ­- Managed Growth's score of 0.00 indicating that The Biotech Growth Trust is being referred to more favorably in the news media.

Company Overall Sentiment
JPMorgan Elect plc ­- Managed Growth Neutral
The Biotech Growth Trust Positive

The Biotech Growth Trust has a net margin of 96.47% compared to JPMorgan Elect plc ­- Managed Growth's net margin of 0.00%. The Biotech Growth Trust's return on equity of 48.26% beat JPMorgan Elect plc ­- Managed Growth's return on equity.

Company Net Margins Return on Equity Return on Assets
JPMorgan Elect plc ­- Managed GrowthN/A N/A N/A
The Biotech Growth Trust 96.47%48.26%12.39%

The Biotech Growth Trust has higher revenue and earnings than JPMorgan Elect plc ­- Managed Growth. JPMorgan Elect plc ­- Managed Growth is trading at a lower price-to-earnings ratio than The Biotech Growth Trust, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
JPMorgan Elect plc ­- Managed Growth£104.78M0.00N/A£0.75N/A
The Biotech Growth Trust£133.86M1.86£83.83M£558.002.44

Summary

The Biotech Growth Trust beats JPMorgan Elect plc ­- Managed Growth on 9 of the 10 factors compared between the two stocks.

How does The Biotech Growth Trust compare to The Merchants Trust?

The Biotech Growth Trust (LON:BIOG) and The Merchants Trust (LON:MRCH) are both small-cap finance companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

10.5% of The Biotech Growth Trust shares are owned by institutional investors. Comparatively, 5.1% of The Merchants Trust shares are owned by institutional investors. 3.1% of The Biotech Growth Trust shares are owned by company insiders. Comparatively, 0.1% of The Merchants Trust shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

The Merchants Trust has higher revenue and earnings than The Biotech Growth Trust. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than The Merchants Trust, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Biotech Growth Trust£133.86M1.86£83.83M£558.002.44
The Merchants Trust£207.14M4.80£109.11M£138.124.90

In the previous week, The Biotech Growth Trust had 1 more articles in the media than The Merchants Trust. MarketBeat recorded 1 mentions for The Biotech Growth Trust and 0 mentions for The Merchants Trust. The Biotech Growth Trust's average media sentiment score of 1.45 beat The Merchants Trust's score of 0.00 indicating that The Biotech Growth Trust is being referred to more favorably in the media.

Company Overall Sentiment
The Biotech Growth Trust Positive
The Merchants Trust Neutral

The Biotech Growth Trust has a beta of 0.606, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, The Merchants Trust has a beta of 1.099, suggesting that its stock price is 10% more volatile than the broader market.

The Merchants Trust has a net margin of 134.08% compared to The Biotech Growth Trust's net margin of 96.47%. The Biotech Growth Trust's return on equity of 48.26% beat The Merchants Trust's return on equity.

Company Net Margins Return on Equity Return on Assets
The Biotech Growth Trust96.47% 48.26% 12.39%
The Merchants Trust 134.08%20.49%7.70%

Summary

The Biotech Growth Trust beats The Merchants Trust on 7 of the 13 factors compared between the two stocks.

How does The Biotech Growth Trust compare to TwentyFour Income?

The Biotech Growth Trust (LON:BIOG) and TwentyFour Income (LON:TFIF) are both small-cap finance companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

In the previous week, TwentyFour Income had 1 more articles in the media than The Biotech Growth Trust. MarketBeat recorded 2 mentions for TwentyFour Income and 1 mentions for The Biotech Growth Trust. The Biotech Growth Trust's average media sentiment score of 1.45 beat TwentyFour Income's score of -0.45 indicating that The Biotech Growth Trust is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
The Biotech Growth Trust
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
TwentyFour Income
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

The Biotech Growth Trust has a net margin of 96.47% compared to TwentyFour Income's net margin of 60.39%. The Biotech Growth Trust's return on equity of 48.26% beat TwentyFour Income's return on equity.

Company Net Margins Return on Equity Return on Assets
The Biotech Growth Trust96.47% 48.26% 12.39%
TwentyFour Income 60.39%6.11%N/A

10.5% of The Biotech Growth Trust shares are held by institutional investors. Comparatively, 37.5% of TwentyFour Income shares are held by institutional investors. 3.1% of The Biotech Growth Trust shares are held by company insiders. Comparatively, 0.1% of TwentyFour Income shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

TwentyFour Income has lower revenue, but higher earnings than The Biotech Growth Trust. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than TwentyFour Income, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Biotech Growth Trust£133.86M1.86£83.83M£558.002.44
TwentyFour Income£57.89M17.22£868.58M£6.9315.34

The Biotech Growth Trust has a beta of 0.606, meaning that its stock price is 39% less volatile than the broader market. Comparatively, TwentyFour Income has a beta of 0.218, meaning that its stock price is 78% less volatile than the broader market.

Summary

The Biotech Growth Trust beats TwentyFour Income on 8 of the 13 factors compared between the two stocks.

How does The Biotech Growth Trust compare to BBGI Global Infrastructure?

BBGI Global Infrastructure (LON:BBGI) and The Biotech Growth Trust (LON:BIOG) are both small-cap finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

BBGI Global Infrastructure has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, The Biotech Growth Trust has a beta of 0.606, suggesting that its share price is 39% less volatile than the broader market.

The Biotech Growth Trust has a net margin of 96.47% compared to BBGI Global Infrastructure's net margin of 61.84%. The Biotech Growth Trust's return on equity of 48.26% beat BBGI Global Infrastructure's return on equity.

Company Net Margins Return on Equity Return on Assets
BBGI Global Infrastructure61.84% 2.52% 3.32%
The Biotech Growth Trust 96.47%48.26%12.39%

The Biotech Growth Trust has higher revenue and earnings than BBGI Global Infrastructure. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than BBGI Global Infrastructure, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BBGI Global Infrastructure£67.98M14.48£54.89M£7.7217.93
The Biotech Growth Trust£133.86M1.86£83.83M£558.002.44

58.9% of BBGI Global Infrastructure shares are held by institutional investors. Comparatively, 10.5% of The Biotech Growth Trust shares are held by institutional investors. 0.5% of BBGI Global Infrastructure shares are held by company insiders. Comparatively, 3.1% of The Biotech Growth Trust shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, The Biotech Growth Trust had 1 more articles in the media than BBGI Global Infrastructure. MarketBeat recorded 1 mentions for The Biotech Growth Trust and 0 mentions for BBGI Global Infrastructure. The Biotech Growth Trust's average media sentiment score of 1.45 beat BBGI Global Infrastructure's score of 0.00 indicating that The Biotech Growth Trust is being referred to more favorably in the news media.

Company Overall Sentiment
BBGI Global Infrastructure Neutral
The Biotech Growth Trust Positive

Summary

The Biotech Growth Trust beats BBGI Global Infrastructure on 10 of the 13 factors compared between the two stocks.

How does The Biotech Growth Trust compare to Baillie Gifford US Growth?

Baillie Gifford US Growth (LON:USA) and The Biotech Growth Trust (LON:BIOG) are both small-cap finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

Baillie Gifford US Growth has a beta of 0.618, indicating that its share price is 38% less volatile than the broader market. Comparatively, The Biotech Growth Trust has a beta of 0.606, indicating that its share price is 39% less volatile than the broader market.

Baillie Gifford US Growth has higher revenue and earnings than The Biotech Growth Trust. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than Baillie Gifford US Growth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Baillie Gifford US Growth£227.65M4.21£84.35M£81.544.24
The Biotech Growth Trust£133.86M1.86£83.83M£558.002.44

In the previous week, The Biotech Growth Trust had 1 more articles in the media than Baillie Gifford US Growth. MarketBeat recorded 1 mentions for The Biotech Growth Trust and 0 mentions for Baillie Gifford US Growth. The Biotech Growth Trust's average media sentiment score of 1.45 beat Baillie Gifford US Growth's score of 0.00 indicating that The Biotech Growth Trust is being referred to more favorably in the news media.

Company Overall Sentiment
Baillie Gifford US Growth Neutral
The Biotech Growth Trust Positive

5.8% of Baillie Gifford US Growth shares are owned by institutional investors. Comparatively, 10.5% of The Biotech Growth Trust shares are owned by institutional investors. 0.2% of Baillie Gifford US Growth shares are owned by insiders. Comparatively, 3.1% of The Biotech Growth Trust shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Baillie Gifford US Growth has a net margin of 96.49% compared to The Biotech Growth Trust's net margin of 96.47%. The Biotech Growth Trust's return on equity of 48.26% beat Baillie Gifford US Growth's return on equity.

Company Net Margins Return on Equity Return on Assets
Baillie Gifford US Growth96.49% 25.27% N/A
The Biotech Growth Trust 96.47%48.26%12.39%

Summary

The Biotech Growth Trust beats Baillie Gifford US Growth on 7 of the 13 factors compared between the two stocks.

Get The Biotech Growth Trust News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIOG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIOG vs. The Competition

MetricThe Biotech Growth TrustCapital Markets IndustryFinance SectorLON Exchange
Market Cap£247.84M£4.88B£13.44B£2.75B
Dividend YieldN/A5.62%4.99%5.11%
P/E Ratio2.4321.6518.7323.13
Price / Sales1.857.774.924.99
Price / Cash87.7429.4320.0420.23
Price / Book1.261.731.762.47
Net Income£83.83M£419.50M£1.32B£5.88B
7 Day Performance-6.36%-2.69%-2.71%-1.94%
1 Month Performance2.27%-2.58%-2.07%-3.34%
1 Year Performance14.75%-2.27%4.55%7.20%

The Biotech Growth Trust Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIOG
The Biotech Growth Trust
N/AGBX 1,354
+1.2%
N/A+14.4%£247.84M£133.86M2.43N/A
JPE
JPMorgan Elect plc ­- Managed Growth
N/AN/AN/AN/A£1.00B£104.78M1,250.00N/A
MRCH
The Merchants Trust
N/AGBX 681.15
+0.6%
N/A+18.5%£1.00B£207.14M4.93N/A
TFIF
TwentyFour Income
N/AGBX 105.68
+0.1%
N/A-5.5%£991.19M£57.89M15.25N/A
BBGI
BBGI Global Infrastructure
N/AGBX 138.50
flat
N/AN/A£984.71M£67.98M17.931,160

Related Companies and Tools


This page (LON:BIOG) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners